# PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes

> **NCT02506647** · PHASE1 · COMPLETED · sponsor: **Gan and Lee Pharmaceuticals, USA** · enrollment: 41 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Gan & Lee insulin glargine followed by Lantus
- **DRUG:** Lantus followed by Gan & Lee insulin glargine

## Key facts

- **NCT ID:** NCT02506647
- **Lead sponsor:** Gan and Lee Pharmaceuticals, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2017-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02506647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02506647, "PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02506647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*